STOCK TITAN

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York, with the chairman and CEO, Jonathan E. Lim, and the CFO and chief business officer, David M. Chacko, taking part in a fireside chat and one-on-one investor meetings. The live audio webcast and archived replay of the event will be available on Erasca's website.
Positive
  • None.
Negative
  • None.

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in a fireside chat on Thursday, February 8, 2024 at 11:00 am Eastern Time. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


The ticker symbol for Erasca, Inc. is ERAS.

The 6th Annual Guggenheim Biotechnology Conference is being held at the St. Regis in New York, New York.

Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the fireside chat.

The live audio webcast of the event will be available online at Erasca.com/events.

An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
Erasca Inc

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ERAS

our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.